Description
A novel potent, selective, peptidic CXCR4 antagonist that interferes with the tumor-protective microenvironment and sensitizes tumor cells to chemotherapy; induces efficient mobilization of HSPCs (hematopoietic stem and progenitor cell) in clinical trails. Blood Cancer Phase 2 Clinical